H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $50 and keeps a Buy rating on the shares. The firm sees an “uneventful” FDA review process for bezuclastinib in non-advanced mastocytosis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM
- Cogent Biosciences price target raised to $67 from $65 at JPMorgan
- Cogent Biosciences Reports Positive Clinical Trial Results
- Cogent Biosciences price target raised to $48 from $45 at Jefferies
- Cogent Biosciences announces results of APEX trial of bezuclastinib